Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) EBT (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of EBT data on record, last reported at -$35.1 million in Q3 2025.

  • For Q3 2025, EBT fell 426.12% year-over-year to -$35.1 million; the TTM value through Sep 2025 reached -$109.4 million, up 18.91%, while the annual FY2024 figure was -$98.1 million, 62.68% up from the prior year.
  • EBT reached -$35.1 million in Q3 2025 per SGMO's latest filing, down from -$20.0 million in the prior quarter.
  • Across five years, EBT topped out at $21.3 million in Q1 2023 and bottomed at -$120.8 million in Q2 2023.
  • Average EBT over 5 years is -$43.0 million, with a median of -$43.9 million recorded in 2022.
  • Peak YoY movement for EBT: plummeted 3645.24% in 2021, then skyrocketed 148.56% in 2023.
  • A 5-year view of EBT shows it stood at -$37.6 million in 2021, then crashed by 37.67% to -$51.7 million in 2022, then dropped by 17.12% to -$60.6 million in 2023, then soared by 60.67% to -$23.8 million in 2024, then tumbled by 47.3% to -$35.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$35.1 million in Q3 2025, -$20.0 million in Q2 2025, and -$30.5 million in Q1 2025.